Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

trastuzumab

Roche Basel Switzerland

AbbVie and Roche’s leukaemia drug venetoclax nears EU market

CHMP grants blood cancer treatment Venclyxto a conditional green light

- PMLiVE

Merck sees €2bn from new launches by 2022

Expects to deliver total sales of €4bn with multiple sclerosis, fertility and cancer drugs portfolio

Roche - Basel

Lucentis claims speedy FDA review for myopia complication

Roche’s drug achieved superior visual acuity gains compared to standard treatment in trials

- PMLiVE

Tesaro’s niraparib threatens Lynparza after acing ovarian cancer trial

Maintenance therapy significantly improved progression-free survival regardless of BRCA status

European regulators give new medicines portal the go-ahead

EMA sets out plans for new online resource for patients, HCPs and academia 

Roche Basel Switzerland

Roche snags pair of FDA breakthrough designations

Accelerates approval process for NSCLC treatment Alecensa and immunotherapy Actemra

- PMLiVE

Man Boobs campaign wins at D&AD Impact Awards

Takes home White Pencil in inaugural awards for creative contribution to society

- PMLiVE

NICE backs Bayer’s Eylea as first-line BRVO treatment

Recommends visual impairment therapy over current laser treatment

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Novartis seeks first-line use for lung cancer drug Zykadia

Looks to go head-to-head with Pfizer/Merck KGaA’s Xalkori and Roche’s Alecensa

- PMLiVE

Market access improvements in Turkey

With 78 million inhabitants, a universal public health insurance scheme, regulations largely harmonised with EU rules and a growing economy, Turkey - the largest market in the Middle East, North...

- PMLiVE

Surviving Brexit

How UK biopharma must adapt to a changing landscape

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links